Background: There have been many studies of the effect of high-dose supplementation of vitamin B 6 on children and adults with autism, with all but one reporting benefits.
INTRODUCTION T
here have been many studies of the effect of high-dose vitamin B 6 supplementation on children and adults with autism, and all but one of those studies have reported positive benefits, usually in about half of the participants. ,* (A summary of these studies is available also. 27 ) Most studies of vitamin B 6 have included magnesium (Mg) to prevent Mg deficiency and hyperactivity. These studies have been somewhat controversial because of some limitations in their methodology, primarily caused by limitations in the diagnostic and assessment tools that were available when the studies were con-ducted. Eleven (11) of the 12 double-blind, placebo-controlled studies reported a favorable response in terms of various behavioral assessments. Only one study of high-dose vitamin B 6 reported negative results, and that study 7 had two limitations. First, it involved only 10 participants, so it was unlikely that any results would be statistically significant. Second, it was a double-blind, placebo-controlled, cross-over study with each phase being only 4 weeks long and with no washout between the phases; the lack of a washout invalidated the "placebo" arm, because B 6 benefits can last for several weeks.
(For example, a study by Coleman et al. 28 of "hyperkinetic" children found that B 6 greatly raised serotonin levels with no drop even 3 weeks after stopping B 6 .) Although all of the studies had some methodologic limitations, all but one found positive benefits from high-dose vitamin B 6 with Mg (in roughly one half of the children and adults with autism).
There was also one study by Tolbert et al. 29 that used a much lower dose (2.86 mg/kg body weight, versus typically 30 mg/kg in most of the other studies). That study did not find a positive benefit, which suggests that the higher dose used in the other studies was necessary.
There have only been two previous studies of the level of vitamin B 6 in children with autism. One study was done by Sankar, 30 who found high levels of vitamin B 6 in approximately 19 autistic children compared to a reference range in the literature, but the reference range was determined with a different method and is questionable. (Other disability groups in their study also had high levels of vitamin B 6 ). The second study was done by the current authors' investigative group. 31 In that study the level of total vitamin B 6 (including both phosphorylated and unphosphorylated forms) was measured in the plasma of 24 unsupplemented children with autism, which was found to be unusually high compared to the testing laboratory's reference range for typical children who were not taking the supplement. Table 1 shows the results of that study. It should be noted that the children with autism were somewhat younger than most of the typical children; and because vitamin B 6 levels increase with age, the difference between children with autism and age-matched typical children is probably even slightly greater. That study was limited because: it depended on the reference range of the testing laboratory (Vitamin Diagnostics, Clifford Beach, NJ); the samples were not tested in a blinded manner; and the samples were not simultaneously measured. Therefore an additional study was needed, which is the focus of the present paper.
This paper reports the results of testing of the plasma levels of vitamin B 6 in 11 more children with autism, who were compared to an additional 11 control subjects. The testing method is identical to that used in a previous study by the current authors' investigative group, so the data for metaanalysis can be pooled. A simple test was used to compare the groups, assuming a normal distribution, with a value of p Ͻ 0.05 being considered statistically significant.
METHODS
The study methodology was approved by the Human Subjects Institutional Review Board at Arizona State University. The parents of all participants provided signed informed consent.
Participant selection
The participants were recruited in Arizona. The selection criteria for the study included: health (no attention-deficit disorder/attention-deficit/ hyperactivity, etc.).
There were 22 applicants (11 children with autism and 11 control subjects) who applied and met the criteria, and they were enrolled in the study. Their demographic characteristics are listed in Table 1 . (This control group was referenced in a previous paper. 31 ) 
Sample mesurement
The samples were measured in a blinded fashion by Vitamin Diagnostics Laboratory using the same methods as in the previous study. 31 
RESULTS
The results of the current and previous measurements are shown in Table 1 . The vitamin B 6 levels of the children with autism in the present study were very close to those of the previous study, with averages of 56 and 55.5 ng/mL, respectively. Also, the vitamin B 6 levels for the controls in the present study (median of 32 Ϯ 9 ng/mL) are similar to those of the laboratory reference range used in the previous study (22-47 ng/mL). (Note that because of a typographic error the units in the previous study were printed incorrectly, and were actually ng/mL).
A comparison of the two groups in the present study shows that the children with ASD had much higher levels of vitamin B 6 than the control subjects (averages of 56 and 36 ng/mL, respectively, medians of 56 and 32 ng/mL, respectively). Based on a two-sided t-test, the difference was statistically significant (p ϭ 0.001), although the small number of participants meant that the statistical power was weak.
As the data in the present study were derived using the same equipment and methods as in the previous study, and as the autism groups in both studies had nearly identical means and medians, it was appropriate to pool the data for the children with autism from both studies for a meta-analysis. In comparing both autism groups (n ϭ 36) and the present control group (the previous study used this control group as a reference), the difference was highly statistically significant (p ϭ 0.00002).
It is interesting to note that the five autistic girls in the combined past/present study had a mean level of 54.6 ng/mL and a median of 60 ng/mL, extremely similar to that of the autistic boys. Larger numbers are needed to be certain, but these limited data suggest that autistic girls also tend to have elevated total vitamin B 6 plasma levels.
DISCUSSION
The present results confirm the previous finding by this investigative group of much higher levels of vitamin B 6 in children with autism not taking the supplement compared to control subjects. In fact, only two of 35 children with autism had values at or below the median of the typical children. Most of the children with autism (77%) had levels that were 2 standard deviations around the median of the control children.
In a previous study, 31 levels of pyridoxal 5 phosphate had been measured and found to be generally much lower than levels in control subjects. In another study, 2 it was found that in autistic children the enzyme pyridoxal kinase (which phosphorylates vitamin B 6 to pyridoxal-5-phosphate-the biochemically active form of vitamin B 6 ) has decreased binding affinity (increased Michaelis constant or K m ) for vitamin B 6 , possibly because of the polymorphic nature of the enzyme. Therefore, it is possible that high doses of vitamin B 6 increased intracellular substrate concentrations and thus activated the defective enzyme. An extensive review by Ames et al. 32 on the molecular basis of disease arising from the mutations in the genes of many enzymes has recently been published. So, a low activity of pyridoxal kinase would ultimately result in low levels of PLP and high levels of pyridoxal. Those results are consistent with the present study, which finds a high amount of total vitamin B 6 (including phosphorylated and unphosphorylated forms), as typically the amount of the unphosphorylated forms is much higher than the phsophorylated forms in the blood.
PLP is an enzymatic cofactor for 113 of the 3870 enzymes catalogued in the ENZYME database (www. expasy.org/enzyme), including the formation of major neurotransmitters such as serotonin, GABA, and the catecholamines. Thus low levels of PLP could have wide-ranging effects on human metabolism, including those on mental function. Normalization of PLP would be expected to improve mental and physical function in some cases. This may explain the many reports of improvement in autistic symptoms upon treatment with high-dose vitamin B 6 .
One might wonder whether similar improvements would occur by simply giving PLP. However, it appears that the phosphate group is removed during digestion, so that PLP would likely have no additional benefit over pyridoxal. Also, the previous study by this investigative group compared 6 months of treatment with PLP or pyridoxine HCl in 184 children with autism, and found adverse effects (worsening of behaviors) in 10% of those children receiving PLP (half the group) versus none in those receiving pyridoxine HCl. Therefore it appears that vitamin B 6 should be given as pyridoxal HCl or pyridoxine HCl, not as PLP.
CONCLUSIONS
Children with autism have abnormally high plasma levels of vitamin B 6 compared to controls. This is consistent with previous reports of an impaired pyridoxal kinase for
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the conversion of pyridoxine to pyridoxal to PLP. This may explain the many published reports of high-dose vitamin B 6 supplementation in some children and adults with autism.
